Aleksandar Videnovic, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| REM Sleep Behavior Disorder | 31 | 2024 | 111 | 8.140 |
Why?
|
| Parkinson Disease | 49 | 2024 | 2893 | 6.330 |
Why?
|
| Disorders of Excessive Somnolence | 9 | 2022 | 279 | 2.800 |
Why?
|
| Circadian Rhythm | 15 | 2025 | 2593 | 2.760 |
Why?
|
| Phototherapy | 7 | 2020 | 368 | 2.270 |
Why?
|
| Neurodegenerative Diseases | 8 | 2023 | 1094 | 2.210 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 4 | 2025 | 197 | 2.090 |
Why?
|
| Chronobiology Disorders | 4 | 2021 | 73 | 1.800 |
Why?
|
| Sleep, REM | 10 | 2023 | 595 | 1.360 |
Why?
|
| Melatonin | 4 | 2021 | 670 | 1.150 |
Why?
|
| Lewy Body Disease | 4 | 2023 | 253 | 1.090 |
Why?
|
| Huntington Disease | 4 | 2023 | 1147 | 1.020 |
Why?
|
| Sleep | 11 | 2024 | 4818 | 0.950 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 2 | 2024 | 263 | 0.900 |
Why?
|
| Sodium Oxybate | 1 | 2023 | 36 | 0.850 |
Why?
|
| Narcolepsy | 2 | 2023 | 200 | 0.840 |
Why?
|
| Multiple System Atrophy | 3 | 2023 | 132 | 0.840 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 4 | 2021 | 13 | 0.710 |
Why?
|
| Carbamates | 1 | 2021 | 192 | 0.670 |
Why?
|
| Phenylalanine | 1 | 2021 | 367 | 0.670 |
Why?
|
| Chronotherapy | 1 | 2019 | 11 | 0.650 |
Why?
|
| Circadian Clocks | 2 | 2021 | 168 | 0.570 |
Why?
|
| Autoantibodies | 2 | 2024 | 2121 | 0.550 |
Why?
|
| alpha-Synuclein | 3 | 2024 | 773 | 0.540 |
Why?
|
| Gait Disorders, Neurologic | 4 | 2022 | 243 | 0.540 |
Why?
|
| Restless Legs Syndrome | 4 | 2021 | 235 | 0.520 |
Why?
|
| Patient Care Management | 1 | 2019 | 303 | 0.520 |
Why?
|
| Fatigue | 2 | 2020 | 1557 | 0.450 |
Why?
|
| Polysomnography | 11 | 2024 | 1871 | 0.440 |
Why?
|
| Multiple Sclerosis | 2 | 2020 | 3250 | 0.440 |
Why?
|
| Dopamine | 3 | 2021 | 1592 | 0.440 |
Why?
|
| Exercise Therapy | 1 | 2019 | 939 | 0.380 |
Why?
|
| Humans | 90 | 2025 | 768171 | 0.370 |
Why?
|
| Gait | 3 | 2022 | 823 | 0.360 |
Why?
|
| Autoimmune Diseases | 1 | 2022 | 2257 | 0.330 |
Why?
|
| Quality of Life | 7 | 2022 | 13490 | 0.330 |
Why?
|
| Sleep Stages | 2 | 2012 | 706 | 0.310 |
Why?
|
| Brain | 7 | 2021 | 27362 | 0.300 |
Why?
|
| Severity of Illness Index | 10 | 2024 | 15949 | 0.280 |
Why?
|
| Movement Disorders | 1 | 2011 | 463 | 0.270 |
Why?
|
| Antiparkinson Agents | 3 | 2024 | 184 | 0.270 |
Why?
|
| Depressive Disorder | 1 | 2019 | 3721 | 0.260 |
Why?
|
| Immunotherapy | 1 | 2022 | 4754 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8052 | 0.230 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2024 | 269 | 0.230 |
Why?
|
| Aged | 32 | 2024 | 171502 | 0.230 |
Why?
|
| Oxadiazoles | 1 | 2024 | 94 | 0.230 |
Why?
|
| Parasomnias | 1 | 2024 | 27 | 0.220 |
Why?
|
| Actigraphy | 2 | 2018 | 527 | 0.220 |
Why?
|
| Levodopa | 1 | 2024 | 221 | 0.210 |
Why?
|
| Pantothenic Acid | 2 | 2020 | 17 | 0.210 |
Why?
|
| Attitude to Health | 1 | 2011 | 2025 | 0.190 |
Why?
|
| Dopamine Agonists | 2 | 2021 | 347 | 0.190 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2021 | 417 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 646 | 0.190 |
Why?
|
| Flecainide | 1 | 2021 | 41 | 0.190 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2005 | 302 | 0.190 |
Why?
|
| Double-Blind Method | 8 | 2024 | 12466 | 0.190 |
Why?
|
| Motor Neuron Disease | 1 | 2022 | 98 | 0.190 |
Why?
|
| Inosine | 1 | 2021 | 129 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2011 | 2381 | 0.180 |
Why?
|
| Deoxycytidine | 1 | 2005 | 887 | 0.180 |
Why?
|
| Benzofurans | 1 | 2021 | 139 | 0.180 |
Why?
|
| Hypotension, Orthostatic | 1 | 2023 | 258 | 0.180 |
Why?
|
| Muscle Rigidity | 1 | 2020 | 41 | 0.170 |
Why?
|
| Middle Aged | 31 | 2024 | 223487 | 0.170 |
Why?
|
| Nervous System Diseases | 3 | 2019 | 1662 | 0.170 |
Why?
|
| Muscle Tonus | 1 | 2020 | 82 | 0.170 |
Why?
|
| Cyclopropanes | 1 | 2021 | 436 | 0.170 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 125 | 0.160 |
Why?
|
| Deep Brain Stimulation | 1 | 2008 | 850 | 0.160 |
Why?
|
| Male | 34 | 2024 | 364731 | 0.160 |
Why?
|
| Mental Status Schedule | 2 | 2010 | 315 | 0.160 |
Why?
|
| Emotions | 1 | 2011 | 2767 | 0.160 |
Why?
|
| Activities of Daily Living | 4 | 2023 | 2430 | 0.160 |
Why?
|
| Self Report | 2 | 2022 | 3773 | 0.150 |
Why?
|
| Female | 35 | 2024 | 397187 | 0.140 |
Why?
|
| Cognition Disorders | 2 | 2020 | 3980 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2022 | 667 | 0.140 |
Why?
|
| Vitamin B Complex | 1 | 2019 | 299 | 0.140 |
Why?
|
| Alzheimer Disease | 3 | 2023 | 8759 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 7140 | 0.140 |
Why?
|
| Disability Evaluation | 2 | 2017 | 1835 | 0.130 |
Why?
|
| Dementia | 2 | 2023 | 2740 | 0.130 |
Why?
|
| Animals | 11 | 2023 | 169285 | 0.130 |
Why?
|
| Uric Acid | 1 | 2021 | 805 | 0.120 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2017 | 984 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2021 | 886 | 0.120 |
Why?
|
| Psychometrics | 1 | 2024 | 3063 | 0.120 |
Why?
|
| Research Design | 3 | 2020 | 6209 | 0.120 |
Why?
|
| Adult | 16 | 2021 | 223646 | 0.110 |
Why?
|
| Brain Stem | 3 | 2021 | 859 | 0.110 |
Why?
|
| Disease Progression | 5 | 2023 | 13668 | 0.110 |
Why?
|
| Amantadine | 1 | 2012 | 59 | 0.100 |
Why?
|
| Period Circadian Proteins | 1 | 2013 | 97 | 0.100 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 26379 | 0.100 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2013 | 141 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1443 | 0.100 |
Why?
|
| Muscle Hypotonia | 1 | 2013 | 166 | 0.100 |
Why?
|
| Isradipine | 1 | 2010 | 12 | 0.090 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2017 | 1141 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2024 | 41753 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 1899 | 0.090 |
Why?
|
| Registries | 2 | 2019 | 8375 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 18349 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15662 | 0.080 |
Why?
|
| Neural Pathways | 1 | 2020 | 3117 | 0.080 |
Why?
|
| Mass Screening | 2 | 2018 | 5458 | 0.080 |
Why?
|
| Electromyography | 1 | 2013 | 1401 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 20225 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2010 | 687 | 0.070 |
Why?
|
| PubMed | 1 | 2008 | 129 | 0.070 |
Why?
|
| Young Adult | 5 | 2019 | 60066 | 0.070 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1106 | 0.070 |
Why?
|
| Globus Pallidus | 1 | 2008 | 248 | 0.070 |
Why?
|
| Neuroprotective Agents | 1 | 2013 | 958 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2017 | 2697 | 0.070 |
Why?
|
| Retina | 1 | 2017 | 2662 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2024 | 2089 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2023 | 65379 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2022 | 13013 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2535 | 0.060 |
Why?
|
| Movement | 2 | 2024 | 1490 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2020 | 914 | 0.060 |
Why?
|
| HELLP Syndrome | 1 | 2005 | 40 | 0.060 |
Why?
|
| Heart Rate | 1 | 2017 | 4214 | 0.060 |
Why?
|
| Patient Selection | 1 | 2017 | 4260 | 0.060 |
Why?
|
| West Nile Fever | 1 | 2005 | 77 | 0.060 |
Why?
|
| Subthalamic Nucleus | 1 | 2008 | 203 | 0.060 |
Why?
|
| Carbidopa | 1 | 2024 | 30 | 0.060 |
Why?
|
| Counseling | 2 | 2023 | 1554 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2017 | 6412 | 0.050 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2023 | 25 | 0.050 |
Why?
|
| Aging | 2 | 2015 | 8743 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2023 | 14783 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2023 | 241 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2005 | 620 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4057 | 0.040 |
Why?
|
| Comorbidity | 3 | 2024 | 10590 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2005 | 1652 | 0.040 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 59626 | 0.040 |
Why?
|
| North America | 1 | 2024 | 1289 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2005 | 809 | 0.040 |
Why?
|
| Prognosis | 4 | 2023 | 30009 | 0.040 |
Why?
|
| Depression | 1 | 2019 | 8230 | 0.040 |
Why?
|
| Genetic Counseling | 1 | 2023 | 635 | 0.040 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2021 | 434 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2018 | 81760 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2021 | 458 | 0.030 |
Why?
|
| Disclosure | 1 | 2023 | 755 | 0.030 |
Why?
|
| Wakefulness | 1 | 2024 | 1284 | 0.030 |
Why?
|
| Consensus | 2 | 2019 | 3211 | 0.030 |
Why?
|
| Dopamine Agents | 1 | 2017 | 188 | 0.030 |
Why?
|
| Reaction Time | 1 | 2022 | 2101 | 0.030 |
Why?
|
| Parkinsonian Disorders | 1 | 2019 | 285 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 30237 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 1140 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2021 | 2661 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 39354 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2020 | 683 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 878 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 4913 | 0.030 |
Why?
|
| Adolescent | 4 | 2019 | 89169 | 0.030 |
Why?
|
| Carcinoma | 1 | 2005 | 2332 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 1737 | 0.030 |
Why?
|
| Clonazepam | 1 | 2013 | 135 | 0.030 |
Why?
|
| Creatine | 1 | 2015 | 427 | 0.030 |
Why?
|
| GABA Modulators | 1 | 2013 | 109 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10397 | 0.030 |
Why?
|
| Phenotype | 2 | 2021 | 16726 | 0.030 |
Why?
|
| Iron | 1 | 2021 | 1813 | 0.030 |
Why?
|
| Health Status | 1 | 2005 | 4091 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 2131 | 0.020 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 707 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2023 | 54924 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 2744 | 0.020 |
Why?
|
| Prevalence | 1 | 2008 | 15869 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 36741 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1008 | 0.020 |
Why?
|
| Social Class | 1 | 2019 | 2008 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2023 | 3914 | 0.020 |
Why?
|
| Forecasting | 1 | 2019 | 2945 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2024 | 3463 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2017 | 22290 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6525 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 5442 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2666 | 0.020 |
Why?
|
| Child | 3 | 2019 | 80917 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 4640 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 3591 | 0.020 |
Why?
|
| Cognition | 1 | 2022 | 7073 | 0.020 |
Why?
|
| West Nile virus | 1 | 2005 | 77 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10763 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 4978 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2649 | 0.010 |
Why?
|
| Hypertension | 2 | 2005 | 8616 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 12543 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4887 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2000 | 150 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2000 | 186 | 0.010 |
Why?
|
| Demography | 1 | 2005 | 1641 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18415 | 0.010 |
Why?
|
| Risk Factors | 2 | 2019 | 74944 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 21207 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 8741 | 0.010 |
Why?
|
| Headache | 1 | 2005 | 1263 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 2005 | 1240 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 82049 | 0.010 |
Why?
|
| United States | 1 | 2019 | 73039 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 23782 | 0.000 |
Why?
|
| Pregnancy | 1 | 2005 | 30255 | 0.000 |
Why?
|